The health resort leaves nothing to chance and is continuously preparing for the 3rd wave of the COVID-19 pandemic: hospitals are prepared to adapt their capacities for patients with COVID-19, the Ministry is actively working to increase the vaccination rate of the population, we have created a number of vaccination options, vaccination centres in hospitals, large-capacity vaccination centres, companies, mobile vaccination teams or clinicians. The Ministry is working in connection with vaccination to intensify communication campaign, in cooperation with the Office of Public Health of the Slovak Republic is working to streamline contact tracking, sequencing positive samples or monitoring of groundwater. At the same time, the Health Department is actively monitoring the state of stocks of medicines at Covid-19 in distribution companies as well as in medical establishments and setting up measures in advance. Stocks of the medicinal product containing bamlanivimab monoclonal antibody are sufficient. The resort provided imports of 5,000 packs of bamlanivimab, currently administered in hospitals to 25 patients. For the treatment of patients with COVID-19 disease, both registered and unregistered medicinal products and unregistered indications are available. Medicinal products containing the active substances tocilizumab, baricitinib, azoximer bromide, bamlanivimab, inosin pranobex and favipiravir and others are available under the permissions issued by the Ministry of Health. Their subsequent use, together with the potential extension of the new portfolio of medicines against COVID-19 disease, will be the subject of further discussion by experts. Medicinal products containing the active substances tocilizumab, baricitinib, bamlanivimab are primarily intended for medical use. Joint public procurement processes for monoclonal antibodies on the part of the European Commission and the Ministry of Health - combinations of bamlanivimab and etesevimab, kasirivimab and imdevimab could be available to EU Member States in the near future.